Remedent, Inc. - Quarterly Report (10-Q)

Table of Contents

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

þ		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2008

o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                      .

Commission File No. 001-15975

REMEDENT, INC.

(Exact Name of Registrant as Specified in Its Charter)

Nevada		86-0837251
(State or Other Jurisdiction		(I.R.S. Employer Identification
Of Incorporation or Organization)		Number)
Xavier De Cocklaan 42, 9831 Deurle, Belgium		N/A
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code 011 32 9 321 70 80

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.

Yes þ       No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o		Accelerated filer o		Non-accelerated filer o		Smaller reporting company þ
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.

Yes o No þ

As of August 18, 2008 there were 18,995,969 outstanding shares of the registrant’s common stock.

 

 

 

---

 

REMEDENT, INC.

FORM 10-Q INDEX

		Page Number
PART I — FINANCIAL INFORMATION			1
Item 1. Financial Statements			1
Condensed Consolidated Balance Sheets as of June 30, 2008 (Unaudited) and March 31, 2008			1
Condensed Consolidated Statements of Operations for the Three Months Ended June 30, 2008 and 2007 (Unaudited)			2
Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three Months Ended June 30, 2008 and 2007 (Unaudited)			3
Condensed Consolidated Statements of Cash Flows for the Three Months Ended June 30, 2008 and 2007 (Unaudited)			4
Notes to Interim Condensed Consolidated Financial Statements (Unaudited)			5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			17
Item 3. Quantitative and Qualitative Disclosures About Market Risk			21
Item 4T. Controls and Procedures			22
PART II — OTHER INFORMATION			23
Item 1. Legal Proceedings			23
Item 1A. Risk Factors			23
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			23
Item 3. Defaults Upon Senior Securities			23
Item 4. Submission of Matters to a Vote of Security Holders			23
Item 5. Other Information			23
Item 6. Exhibits			26
Signature Page
EXHIBIT 31.1
EXHIBIT 31.2
EXHIBIT 32.1
EXHIBIT 32.2

 

---

Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

REMEDENT, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

		June 30, 2008				March 31, 2008
		(unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents		$	1,467,692			$	1,728,281
Accounts receivable, net of allowance for doubtful accounts of $32,083 at June 30, 2008 and $32,181 at March 31, 2008			2,444,089				1,902,920
Inventories, net			1,450,696				1,360,709
Prepaid expense			877,486				970,173
Total current assets			6,239,963				5,962,083
PROPERTY AND EQUIPMENT, NET			907,876				692,609
OTHER ASSETS			675,000				675,000
Patents, net			107,680				15,827
TOTAL ASSETS		$	7,930,519			$	7,445,519
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Current portion, long term debt		$	67,344			$	58,583
Line of Credit			853,621				779,718
Accounts payable			1,854,429				2,002,439
Accrued liabilities			816,023				781,737
Income taxes payable			15,122				15,121
Total current liabilities			3,606,539				3,637,598
LONG TERM DEBT			168,604				94,754
STOCKHOLDERS’ DEFICIT:
Preferred Stock $0.001 par value (10,000,000 shares authorized, none issued and outstanding)							—
Common stock, $0.001 par value; (50,000,000 shares authorized, 18,637,803 shares issued and outstanding at June 30, 2008 and March 31, 2008 )			18,638				18,638
Additional paid-in capital			18,014,107				17,929,992
Accumulated deficit			(13,932,611	)			(14,263,113	)
Accumulated other comprehensive income (loss) (foreign currency translation adjustment)			55,242				27,650
Total stockholders’ equity (deficit)			4,155,376				3,713,167
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	7,930,519			$	7,445,519

COMMITMENTS (Note 18)
SUBSEQUENT EVENT (Note 19)

The accompanying notes are an integral part of these consolidated financial statements.

1

---

Table of Contents

REMEDENT, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

		For the three months ended
		June 30,
		2008				2007
Net sales		$	3,635,479			$	1,244,657
Cost of sales			1,269,424				665,428
Gross profit			2,366,055				579,229
Operating Expenses
Research and development			124,958				29,389
Sales and marketing			671,299				103,241
General and administrative			1,130,313				744,481
Depreciation and amortization			91,261				65,634
TOTAL OPERATING EXPENSES			2,017,831				942,745
INCOME (LOSS) FROM OPERATIONS			348,224				(363,516	)
OTHER INCOME (EXPENSES)
Interest expense			(35,343	)			(28,829	)
Other income			17,621				1,392
TOTAL OTHER INCOME (EXPENSES)			(17,723	)			(27,437	)
NET INCOME (LOSS) BEFORE TAX		$	330,501			$	(390,953	)
INCOME (LOSS) PER SHARE
Basic		$	0.02			$	(0.03	)
Fully diluted		$	0.01			$	(0.03	)
WEIGHTED AVERAGE SHARES OUTSTANDING
Basic			18,637,803				13,611,630
Fully diluted			27,000,995				13,611,630

The accompanying notes are an integral part of these consolidated financial statements.

2

---

Table of Contents

REMEDENT, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

		For the three months ended June 30,
		(Unaudited)
		2008				2007
Net Income (Loss)		$	330,501			$	(390,953	)
OTHER COMPREHENSIVE
INCOME (LOSS):
Foreign currency translation adjustment			27,592				4,600
Comprehensive income (loss)		$	358,093			$	(386,353	)

3

---

Table of Contents

REMEDENT, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

		For the three months ended
		June 30,
		2008				2007
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)		$	330,501			$	(390,953	)
Adjustments to reconcile net income (loss) to net cash used by operating activities Depreciation and amortization			91,261				65,634
Inventory reserve			(48	)			—
Allowance for doubtful accounts			(98	)			—
Value of stock options issued to employees			88,425				—
Changes in operating assets and liabilities:
Accounts receivable			(541,169	)			296,096
Inventories			(89,987	)			211,818
Prepaid expenses			92,687				(122,238	)
Accounts payable			(148,010	)			382,544
Accrued liabilities			34,286				855,583
Net cash provided by (used by) operating activities			(142,152	)			1,298,484
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of equipment			(287,613	)			(50,364	)
Net cash used by investing activities			(287,613	)			(50,364	)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from private placement			—				6,045,294
Net proceeds from (repayments of) capital lease note payable			82,611				(11,201	)
Proceeds from (repayments of) line of credit			34,286				(522,226	)
Net cash provided by financing activities			116,897				5,511,867
NET (DECREASE) INCREASE IN CASH			(312,868	)			6,759,987
Effect of exchange rate changes on cash and cash equivalents			52,279				6,756
CASH AND CASH EQUIVALENTS, BEGINNING			1,728,281				126,966
CASH AND CASH EQUIVALENTS, ENDING		$	1,467,692			$	6,893,709
Supplemental Information:
Interest paid		$	23,443			$	23,376
Income taxes paid		$	—			$	—

The accompanying notes are an integral part of these consolidated financial statements.

4

---

Table of Contents

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

1.		BACKGROUND AND ORGANIZATION
		The Company is a manufacturer and distributor of cosmetic dentistry products, including a full line of professional dental and retail “Over-The-Counter” tooth whitening products which are distributed in Europe, and recently in Asia and the United States. The Company manufactures many of its products in its facility in Deurle, Belgium as well as outsourced manufacturing in China. The Company distributes its products using both its own internal sales force and through the use of third party distributors.
2.		SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
		Organization and Principles of Consolidation
		The accompanying consolidated financial statements include the accounts of Remedent, Inc. (formerly Remedent USA, Inc.), a Nevada corporation, and its four subsidiaries, Remedent N.V. (Belgian corporation) located in Deurle, Belgium, Remedent Professional, Inc. (incorporated in California) and a subsidiary of Remedent Professional Holdings, Inc., Remedent Asia Pte. Ltd, a wholly-owned subsidiary formed under the laws of Singapore, and Sylphar N.V. (incorporated in Belgium as a wholly owned subsidiary on September 24, 2007), (collectively, the “Company”). Remedent, Inc. is a holding company with headquarters in Deurle, Belgium. Remedent Professional, Inc. and Remedent Professional Holdings, Inc. have been dormant since inception. Remedent Asia Pte. Ltd., commenced operations as of July 2005. All significant inter-company accounts and transactions have been eliminated in the consolidated financial statements. Corporate administrative costs are not allocated to subsidiaries.
		Interim Financial Information
		The interim consolidated financial statements of Remedent, Inc. and Subsidiaries (the “Company”) are condensed and do not include some of the information necessary to obtain a complete understanding of the financial data. Management believes that all adjustments necessary for a fair presentation of results have been included in the unaudited consolidated financial statements for the interim periods presented. Operating results for the three months ended June 30, 2008, are not necessarily indicative of the results that may be expected for the year ended March 31, 2009. Accordingly, your attention is directed to footnote disclosures found in the Annual Report on Form 10-KSB for the year ended March 31, 2008, and particularly to Note 1, which includes a summary of significant accounting policies.
		Basis of Presentation
		The Company’s financial statements have been prepared on an accrual basis of accounting, in conformity with accounting principles generally accepted in the United States of America. These principles contemplate the realization of assets and liquidation of liabilities in the normal course of business. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
		Revenue Recognition
		The Company recognizes revenue from product sales when persuasive evidence of a sale exists: that is, a product is shipped under an agreement with a customer; risk of loss and title has passed to the customer; the fee is fixed or determinable; and collection of the resulting receivable is reasonably assured. Sales allowances are estimated based upon historical experience of sales returns.

5

---

Table of Contents

		Impairment of Long-Lived Assets
		Long-lived assets consist primarily of patents and property and equipment. The recoverability of long-lived assets is evaluated by an analysis of operating results and consideration of other significant events or changes in the business environment. If impairment exists, the carrying amount of the long-lived assets is reduced to its estimated fair value, less any costs associated with the final settlement. As of June 30, 2008, management believes there was no impairment of the Company’s long-lived assets.
		Pervasiveness of Estimates
		The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, the Company evaluates estimates and judgments, including those related to revenue, bad debts, inventories, fixed assets, intangible assets, stock based compensation, income taxes, and contingencies. Estimates are based on historical experience and on various other assumptions that the Company believes reasonable in the circumstances. The results form the basis for making judgments about the carrying vales of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
		Cash and Cash Equivalents
		The Company considers all highly liquid investments with maturities of three months or less to be cash or cash equivalents.
		Accounts Receivable and Allowance for Doubtful Accounts
		The Company sells professional dental equipment to various companies, primarily to distributors located in Western Europe. The terms of sales vary by customer, however, generally are 2% 10 days, net 30 days. Accounts receivable is reported at net realizable value and net of allowance for doubtful accounts. The Company uses the allowance method to account for uncollectible accounts receivable. The Company’s estimate is based on historical collection experience and a review of the current status of trade accounts receivable.
		Inventories
		The Company purchases certain of its products in components that require assembly prior to shipment to customers. All other products are purchased as finished goods ready to ship to customers.
		The Company writes down inventories for estimated obsolescence to estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected, then additional inventory write-downs may be required. Inventory reserves for obsolescence totaled $15,764 at June 30, 2008 and $15,812 at March 31, 2008.
		Prepaid Expense
		The Company’s prepaid expense consists of prepayments to suppliers for inventory purchases and to the Belgium customs department, to obtain an exemption of direct VAT payments for imported goods out of the European Union (“EU”). This prepayment serves as a guarantee to obtain the facility to pay VAT at the moment of sale and not at the moment of importing goods at the border. Prepaid expenses also include VAT payments made for goods and services in excess of VAT payments received from the sale of products as well as amounts for other prepaid operating expenses.

6

---

Table of Contents

		Property and Equipment
		Property and equipment are stated at cost. Major renewals and improvements are charged to the asset accounts while replacements, maintenance and repairs, which do not improve or extend the lives of the respective assets, are expensed. At the time property and equipment are retired or otherwise disposed of, the asset and related accumulated depreciation accounts are relieved of the applicable amounts. Gains or losses from retirements or sales are credited or charged to income.
		The Company depreciates its property and equipment for financial reporting purposes using the straight-line method based upon the following useful lives of the assets:

Tooling		3 Years
Furniture and fixtures		4 Years
Machinery and Equipment		4 Years

		Patents
		Patents consist of the costs incurred to purchase patent rights and are reported net of accumulated amortization. Patents are amortized using the straight-line method over a period based on their contractual lives.
		Research and Development Costs
		The Company expenses research and development costs as incurred.
		Advertising
		Costs incurred for producing and communicating advertising are expensed when incurred and included in sales and marketing and general and administrative expenses. For the three month periods ended June 30, 2008 and June 30, 2007, advertising expense was $86,600 and $38,331, respectively.
		Income taxes
		Income taxes are provided in accordance with Statement of Financial Accounting Standards No. 109 (SFAS 109), “ Accounting for Income Taxes .” Deferred taxes are recognized for temporary differences in the bases of assets and liabilities for financial statement and income tax reporting as well as for operating losses and credit carry forwards. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences. The components of the deferred tax asset and liability are individually classified as current and non-current based on their characteristics.
		Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
		Warranties
		The Company typically warrants its products against defects in material and workmanship for a period of 18 months from shipment. Based upon historical trends and warranties provided by the Company’s suppliers and sub-contractors, the Company has made a provision for warranty costs of $23,646 and $23,718 as of June 30, 2008 and March 31, 2008, respectively.
		Segment Reporting
		Statement of Financial Accounting Standards No. 131 (“SFAS 131”), “ Disclosure About Segments of an Enterprise and Related Information” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. The Company’s management considers its business to comprise one segment for reporting purposes.

7

---

Table of Contents

		Computation of Earnings (Loss) per Share
		Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income (loss) per common share attributable to common stockholders assuming dilution is computed by dividing net income by the weighted average number of shares of common stock outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Potential common shares related to stock options and stock warrants are excluded from the computation when their effect is anti-dilutive.
		Conversion of Foreign Currencies
		The reporting currency for the consolidated financial statements of the Company is the U.S. dollar. The functional currency for the Company’s European subsidiaries, Remedent N.V. and Sylphar N.V., is the Euro, for Remedent Asia the Singapore Dollar. Finally, the functional currency for Remedent Professional, Inc. is the U.S. dollar. The Company translates foreign currency statements to the reporting currency in accordance with FASB 52. The assets and liabilities of companies whose functional currency is other that the U.S. dollar are included in the consolidation by translating the assets and liabilities at the exchange rates applicable at the end of the reporting period. The statements of income of such companies are translated at the average exchange rates during the applicable period. Translation gains or losses are accumulated as a separate component of stockholders’ equity.
		Comprehensive Income (Loss)
		The Company has adopted the provisions of Statement of Financial Accounting Standards No. 130, “ Reporting Comprehensive Income ” (“SFAS No. 130”). SFAS No. 130 establishes standards for the reporting and display of comprehensive income, its components and accumulated balances in a full set of general purpose financial statements. SFAS No. 130 defines comprehensive income (loss) to include all changes in equity except those resulting from investments by owners and distributions to owners, including adjustments to minimum pension liabilities, accumulated foreign currency translation, and unrealized gains or losses on marketable securities.
		The Company’s only component of other comprehensive income is the accumulated foreign currency translation consisting of gains of $27,592 and $4,600 for the three month periods ended June 30, 2008 and June 30, 2007, respectively. These amounts have been recorded as a separate component of stockholders’ equity.
		Stock Based Compensation
		In December 2004, the Financial Accounting Standards Board issued SFAS No. 123R, “ Share-Based Payment .” Subsequently, the Securities and Exchange Commission (“SEC”) provided for a phase-in implementation process for SFAS No. 123R, which required adoption of the new accounting standard no later than January 1, 2006. SFAS No. 123R requires accounting for stock options using a fair-value-based method as described in such statement and recognize the resulting compensation expense in the Company’s financial statements. Prior to January 1, 2006, the Company accounted for employee stock options using the intrinsic value method under APB No. 25, “Accounting for Stock Issued to Employees” and related Interpretations, which generally resulted in no employee stock option expense. The Company adopted SFAS No. 123R on January 1, 2006 and does not plan to restate financial statements for prior periods. The Company plans to continue to use the Black-Scholes option valuation model in estimating the fair value of the stock option awards issued under SFAS No. 123R. The adoption of SFAS No. 123R has a material impact on the Company’s results of operations. For the three month periods ended June 30, 2008 and June 30, 2007, equity compensation in the form of stock options and grants of restricted stock totaled $88,425 and $nil, respectively.

8

---

Table of Contents

		Recent Accounting Pronouncements
		In March 2008, the FASB issued SFAS No. 161, “ Disclosures about Derivative Instruments and Hedging Activities” . This statement changes the disclosure requirements for derivative instruments and hedging activities. Entities are required to provide enhanced disclosures about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, and its related interpretations, and (c) how derivative instruments and related hedged items affect an entity’s financial position, financial performance, and cash flows. This statement is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008 (the Company’s fiscal year beginning April 1, 2009), with early application encouraged. This statement encourages, but does not require, comparative disclosures for earlier periods at initial adoption. Management is in the process of evaluating the impact the future application of this pronouncement may have on its consolidated financial statements.
		In December 2007, the FASB issued SFAS No. 141 (Revised 2007) “ Business Combinations ”. SFAS 141 (Revised) establishes principles and requirements for how the acquirer of a business recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree. The statement also provides guidance for recognizing and measuring the goodwill acquired in the business combination and determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. The guidance will become effective for the Company’s fiscal year beginning April 1, 2009. Management is in the process of evaluating the impact SFAS 141 (Revised) will have on the Company’s financial statements upon adoption.
		In December 2007, the FASB issued SFAS No. 160 “ Noncontrolling Interests in Consolidated Financial Statements — an amendment of ARB No. 51 ”. SFAS 160 establishes accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. The guidance will become effective for the Company’s fiscal year beginning April 1, 2009. Management is in the process of evaluating the impact SFAS 160 will have on the Company’s financial statements upon adoption.
3.		PRIVATE PLACEMENT
		On June 25, 2007, the Company completed its private offering of 5,600,000 shares of its common stock, par value $.001 per share at a purchase price of $1.25 per share (the “Shares”) and warrants to purchase 4,200,000 shares of common stock, par value $.001 per share, at an exercise price of $1.55 per share (the “Warrants”) to certain institutional and accredited investors, for an aggregate purchase price of $7,000,000 (the “Offering”).
		Under the terms of the Offering, the Warrants are exercisable for a period of five years and entitle the holder to purchase one share of restricted common stock (the “Warrant Shares”) for $1.55 per Warrant Share. The Company also has the right to redeem the Warrants for $0.001 per Warrant Share covered by the Warrants if the Shares trade on the OTC Electronic Bulletin Board or similar market above $5.25 per share for 20 consecutive trading days following the initial effective date of the registration statement covering the resale of the Shares and Warrant Shares, based upon the closing bid price for the Shares for each trading day (the “Redemption Right”). Once the Redemption Right vests, the Company has the right, but not the obligation, to redeem the Warrants for $0.001 per Warrant Share covered by the Warrants upon 30 days written notice to the holders of the Warrants.
		Under the terms of the Purchase Agreement and the Registration Rights Agreement, the Company was required to prepare and file with the Securities and Exchange Commission (the “Commission”) a registration statement covering the resale of the Shares and the Warrant Shares. The Company agreed to prepare and file a registration statement covering the resale no later than 30 days after the Closing. The registration statement became effective October 23, 2007.
		The Company engaged Roth Capital Partners, LLC, as its exclusive agent to offer the Shares and Warrants (the “Placement Agent”). The Placement Agent is entitled to a fee equal to ten percent (10%) of the gross proceeds derived from the Offering, of which the Placement Agent may, at its option, receive up to 2% of its 10% fee in securities issued in the Offering. Further, the Company agreed to pay the Placement Agent 5% of the exercise price of the Warrants promptly following the Company’s receipt thereof. In addition, the Company agreed to reimburse the Placement Agent for its out-of-pocket expenses related to the Offering, including an up front payment of $25,000 to cover such expenses, of which any unused amount will be netted against the Placement Agent’s 10% fee.

9

---

Table of Contents

		As of June 30, 2008, the total costs of this private placement were $1,228,808, comprising of: commissions of $762,505; out-of-pocket costs of $25,000; professional fees of $369,323 and direct travel costs of $71,980; and have been recorded against share capital as a cost of financing.
		The Offering was conducted in reliance upon an exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”), including, without limitation, that under Section 506 of Regulation D promulgated under the Securities Act. The Units were offered and sold by the Company to accredited investors in reliance on Section 506 of Regulation D of the Securities.
4.		CONCENTRATION OF RISK
		Financial Instruments — Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of trade accounts receivable.
		Concentrations of credit risk with respect to trade receivables are normally limited due to the number of customers comprising the Company’s customer base and their dispersion across different geographic areas. At June 30, 2008 one customer accounted for 44% of the Company’s trade accounts receivable. The Company performs ongoing credit evaluations of its customers and normally does not require collateral to support accounts receivable.
		Purchases — The Company has diversified its sources for product components and finished goods and, as a result, the loss of a supplier would not have a material impact on the Company’s operations. For the three month period ended June 30, 2008, the Company had five suppliers who accounted for a total of 25% of gross purchases. For the three month period ended June 30, 2007, the Company had five suppliers who accounted for a total of 29% of gross purchases.
		Revenues — For the three months ended June 30, 2008 the Company had one customer that accounted for 36% of total revenues. For the three month period ended June 30, 2007 the Company had five customers that accounted for 32% of total revenues.
5.		ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS
		A summary of accounts receivable and allowance for doubtful accounts as of June 30, 2008 and March 31, 2008 is as follows:

		June 30, 2008				March 31, 2008
Accounts receivable, gross		$	2,476,172			$	1,935,101
Less: allowance for doubtful accounts			(32,083)				(32,181	)
Accounts receivable, net		$	2,444,089			$	1,902,920

6.		INVENTORIES
		Inventories are stated at the lower of cost (weighted average) or market. Inventory costs include material, labor and manufacturing overhead. Individual components of inventory are listed below as follows:

		June 30, 2008				March 31, 2008
Raw materials		$	30,681			$	29,788
Components			1,090,416				970,101
Finished goods			345,363				376,632
			1,466,460				1,376,521
Less: reserve for obsolescence			(15,764)				(15,812	)
Net inventory		$	1,450,696			$	1,360,709

10

---

Table of Contents

7.		PREPAID EXPENSES
		Prepaid expenses are summarized as follows:

		June 30, 2008				March 31, 2008
Prepaid materials and components		$	621,666			$	588,639
Prepaid Belgium income taxes			—				79,060
Prepaid consulting			73,861				62,237
VAT payments in excess of VAT receipts			82,674				117,467
Royalties			39,410				39,530
Prepaid trade show expenses			15,408				25,276
Prepaid rent			15,347				10,812
Other			29,119				47,152
		$	877,486			$	970,173

8.		PROPERTY AND EQUIPMENT
		Property and equipment are summarized as follows:

		June 30, 2008				March 31, 2008
Furniture and Fixtures		$	198,789			$	182,079
Machinery and Equipment			984,154				801,251
Tooling			342,450				254,450
			1,525,393				1,237,780
Accumulated depreciation			(617,517)				(545,171	)
Property & equipment, net		$	907,876			$	692,609

9.		LONG TERM INVESTMENTS AND ADVANCES
		Innovative Medical & Dental Solutions, LLC (“IMDS, LLC”)
		Effective July 15, 2007 the Company entered into a Limited Liability Company Merger and Equity Reallocation Agreement (the “Participation Agreement”) through its subsidiary, Remedent N.V. Pursuant to the terms of the Participation Agreement, the Company has acquired a 10% equity interest in IMDS, LLC in consideration for $300,000 which was converted against IMDS receivables.
		The agreement stipulates certain exclusive world wide rights to certain tooth whitening technology, and the right to purchase at standard cost certain whitening lights and accessories and to sell such lights in markets not served by the LLC. The terms of the Participation Agreement also provide that Remedent N.V. has the first right to purchase additional equity. Parties to the Participation Agreement include two officers of IMDS, LLC, and an individual who is both an officer and director of Remedent Inc., and certain unrelated parties.
		IMDS, LLC is registered with the Secretary of the State of Florida as a limited liability company and with the Secretary of the State of California as a foreign corporation authorized to operate in California. IMDS, LLC is merging with White Science World Wide, LLC, a limited liability company organized under the laws of the State of Georgia. The merged companies are operating as a single entity as IMDS, LLC, a Florida limited liability company.
		Soca Networks Singapore (“Soca”)
		Pursuant to the terms of a letter of intent dated December 17, 2007, the Company has agreed to purchase 20% of Soca for a total purchase price of $750,000. Half of the purchase price has been advanced $375,000 to Soca as a down payment, pending completion of the agreement terms. The balance of $375,000 is to be paid through the issuance of 220,588 shares of the Company’s common stock. The final agreement is currently being negotiated and management expects to close the agreement within the first half of the new fiscal year 2009.

11

---

Table of Contents

10.		LICENSED PATENTS
		Teeth Whitening Patents
		In October 2004, the Company acquired from the inventor the exclusive, perpetual license to two issued United States patents which are applicable to several teeth whitening products currently being marketed by the Company. Pursuant to the terms of the license agreement, the Company was granted an exclusive, worldwide, perpetual license to manufacture, market, distribute and sell the products contemplated by the patents subject to the payment of $65,000 as reimbursement to the patent holder for legal and other costs associated with obtaining the patents, which was paid in October 2004, and royalties for each unit sold subject to an annual minimum royalty of $100,000 per year. The Company is amortizing the initial cost of $65,000 for these patents over a ten year period and accordingly has recorded $24,375 of accumulated amortization for this patent as of June 30, 2008. The Company accrues this royalty when it becomes payable to inventory therefore no provision has been made for this obligation as of June 30, 2008 (2007-Nil).
		Universal Applicator Patent
		In September 2004, the Company entered into an agreement with Lident N.V. (“Lident”), a company controlled by Mr. De Vreese, the Company’s Chairman, to obtain an option, exercisable through December 31, 2005, to license an international patent (excluding the US) and worldwide manufacturing and distribution rights for a potential new product which Lident had been assigned certain rights by the inventors of the products, who are unrelated parties, prior to Mr. De Vreese association with the Company. The patent is an Italian patent which relates to a single use universal applicator for dental pastes, salves, creams, powders, liquids and other substances where manual application could be relevant. The Company has filed to have the patent approved throughout Europe. The agreement required the Company to advance to the inventors through Lident a fully refundable deposit of € 100,000 subject to the Company’s due diligence regarding the enforceability of the patent and marketability of the product, which, if viable, would be assigned to the Company for additional consideration to the inventors of € 100,000 and an ongoing royalty from sales of products related to the patent equal to 3% of net sales and, if not viable, the deposit would be repaid in full by Lident. The consideration the Company had agreed to pay Lident upon the exercise of the option is the same as the consideration Lident is obligated to pay the original inventors. Consequently, Lident would not have profited from the exercise of the option. Furthermore, at a meeting of the Company’s Board of Directors on July 13, 2005, the Board accepted Lident’s offer to facilitate an assignment of Lident’s intellectual property rights to the technology to the Company in exchange for the reimbursement of Lident’s actual costs incurred relating to the intellectual property. Consequently, when the Company exercises the option, all future payments, other than the reimbursement of costs would be paid directly to the original inventors and not to Lident.
		On December 12, 2005, the Company exercised the option and the Company and the patent holder agreed to revise the assignment agreement whereby the Company agreed to pay € 50,000 additional compensation in the form of prepaid royalties instead of the € 100,000 previously agreed. The Company paid € 25,000 in September 2005 and the remaining € 25,000 was paid in the period ended June 30, 2008. The patent is being amortized over five (5) years and accordingly, the Company has recorded $61,411 of accumulated amortization for this patent as of June 30, 2008.
11.		LINE OF CREDIT
		On October 8, 2004, our wholly owned subsidiary, Remedent N.V., obtained a mixed-use line of credit facility with Fortis Bank, a Belgian bank, for € 1,070,000 (the “Facility”). The Facility was secured by a first lien on the assets of Remedent N.V. The purpose of the Facility is to provide working capital to grow our business and to finance certain accounts receivable as necessary. Since opening the Facility in 2004, Remedent N.V. and Fortis Bank have subsequently amended the Facility several times to increase or decrease the line of credit. On May 3, 2005 the Facility was amended to decrease the line of credit to € 1,050,000. On March 13, 2006 the Facility was amended to increase the mixed-use line of credit to € 2,300,000, consisting of a € 1,800,000 credit line based on the eligible accounts receivable and a € 500,000 general line of credit. The latest amendment to the Facility, dated January 3, 2008, amended and decreased the mixed-use line of credit to € 2,050,000, to be used by Remedent NV and/or Sylphar NV. Each line of credit carries its own interest rates and fees as provided in the Facility.

12

---

Table of Contents

		Remedent N.V. and Sylphar N.V. are currently only utilizing two lines of credit, advances based on account receivables and the straight loan. As of June 30, 2008 and March 31, 2008, Remedent N.V. and Sylphar N.V. had in aggregate, $853,621 and $779,718 in advances outstanding, respectively, under this mixed-use line of credit facility.
12.		LONG TERM DEBT
		On June 15, 2005, the Company entered into two five year capital lease agreements for manufacturing equipment totaling € 70,296 (US $85,231). On October 24, 2006, the Company entered into another five year capital lease agreement for additional manufacturing equipment totaling € 123,367 (US $157,503). On May 15, 2008, the company entered into a third capital lease agreement over a three year period for additional manufacturing equipment totaling € 63,395 (US $ 98,516).The leases require monthly payments of principal and interest at 7.43% of € 1,258 (US$1,983 at June 30, 2008) for the first two leases and 9.72% of € 2,276 (US$3,588 at June 30, 2008) and provide for buyouts at the conclusion of the five year term of € 2,820 (US$4,445) or 4.0% of original value for the first two contracts and € 4,933 (US $7,776) or 4.0 % of the original value for the second contract. Concerning the third lease contract requires monthly payments of principal and interest at 9,40% of € 1,909 (US $ 3,009 at June 30, 2008) and provides for buyout at the conclusion of the three year term of € 633,95 (US $ 999) or 1% of the original value of this contract.
		The book value as of June 30, 2008 and March 31, 2008 of the equipment subject to the foregoing leases are $235,947 and $149,673, respectively.
13.		DUE TO RELATED PARTIES AND RELATED PARTY TRANSACTIONS
		Borrowings from employees and entities controlled by officers of the Company are, unsecured, non-interest bearing, and due on demand.
		Transactions with related parties consisted of the following:
		Compensation:
		During the three month periods ended June 30, 2008 and 2007 respectively, the Company incurred $179,632 and $156,594 respectively, as compensation for all directors and officers.
		Sales Transactions:
		One of the Company’s directors owns a minority interest in a client company, IMDS Inc., to which goods were sold during the quarter ended June 30, 2008 and 2007 totaling $34,980 and $355 respectively. Accounts receivable at year end with this customer totaled $91,533 and $392,057 as at March 31, 2008 and 2007 respectively.
		Accounts receivable with this customer totaled $47,429 and $361,129 as at June 30, 2008 and 2007 respectively.
		All related party transactions involving provision of services or tangible assets were recorded at the exchange amount, which is the value established and agreed to by the related parties reflecting arms length consideration payable for similar services or transfers.

13

---

Table of Contents

14.		ACCRUED LIABILITIES
		Accrued liabilities are summarized as follows:

		June 30, 2008				March 31, 2008
Accrued employee benefit taxes and payroll		$	142,247			$	178,645
Accrued Travel			11,823				17,667
Advances and deposits			6,655				212,736
Commissions			254,861				130,875
Accrued audit and tax preparation fees			8,343				4,000
Reserve for warranty costs			23,646				23,718
Accrued interest			—				984
Accrued consulting fees			3,288				35,204
Other accrued expenses			271,112				177,908
		$	816,023			$	781,737

15.		EQUITY COMPENSATION PLANS
		The Board of Directors and stockholders approved the Nonstatutory Stock Option Plan (the “2001 Plan”) and adopted it on May 29, 2001. The Company has reserved 250,000 shares of its common stock for issuance to the directors, employees and consultants under the Plan. The Plan is administered by the Board of Directors. Vesting terms of the options range from immediately to five years.
		Pursuant to an Information Statement on Schedule 14C mailed on May 9, 2005 to all stockholders of record as of the close of business on February 1, 2005 and became effective June 3, 2005, the Company authorized the implementation of a 2004 Incentive and Nonstatutory Stock Option Plan (“2004 Plan”) reserving 800,000 shares of common stock for issuance to employees, directors and consultants of the Company or any subsidiaries. This plan became effective as of June 3, 2005 after the Company had completed a one for twenty reverse split.
		On August 17, 2007, pursuant to the terms of the Company’s 2004 Plan, the Company granted to an employee 100,000 options to purchase the Company’s common stock at a price of $1.50 per share. These options will vest over the next 3 years and are exercisable for a period of 5 years. The Company valued the foregoing options using the Black Scholes option pricing model using the following assumptions: no dividend yield; expected volatility rate of 115%; risk free interest rate of 4.75% and an average life of 5 years resulting in a value of $1.24 per option granted. The value of these options will be recognized on a straight-line basis over the next three years and accordingly a value of $28,780 has been recorded in the year ended March 31, 2008.
		On September 21, 2007 the Company granted to employees and directors a total of 570,000 options to purchase the Company’s common stock at a price of $1.75 per share. These options will vest over the next 3 years and are exercisable for a period of 10 years. The Company valued the foregoing options using the Black Scholes option pricing model using the following assumptions: no dividend yield; expected volatility rate of 115%; risk free interest rate of 4.75% and an average life of 7 years resulting in a value of $1.47 per option granted. The value of these options will be recognized on a straight-line basis over the next three years and accordingly a value of $88,425 has been recorded in the three months ended June 30, 2008 (2007 — $nil).

14

---

Table of Contents

A summary of the option activity for the three months ended June 30, 2008 pursuant to the terms of the plans is as follows:

		2001 Plan								2004 Plan								Other
						Weighted								Weighted								Weighted
		Outstanding				Average				Outstanding				Average				Outstanding				Average
		Options				Exercise Price				Options				Exercise Price				Options				Exercise Price
Options outstanding , March 31, 2008			222,500			$	1.29				730,666			$	4.46				150,000			$	1.75
Granted			—				—				—				—				—				—
Exercised			—				—				—				—				—				—
Cancelled or expired			—				—				—				—				—				—
Options outstanding, June 30, 2008			222,500			$	1.29				730,666			$	2.17				150,000			$	1.75
Options exercisable June 30, 2008			222,500			$	1.29				210,666			$	4.25				—				—
Exercise price range		$	1.00 to $4.00							$	1.50 to $4.00							$	1.75
Weighted average remaining life		3.8 years								7.8 years								9.23 years
Shares available for future issuance			27,500								69,334								N/A

A summary of the Company’s equity compensation plans approved and not approved by shareholders is as follows:

Number of

Number of securities

securities to be

remaining available for

issued upon

future issuance under

exercise of

Weighted-average

equity compensation

outstanding

exercise price of

plans (excluding

options, warrants

outstanding options

securities reflected

Plan Category

and right

warrants and rights

in column (a))

Equity Compensation Plans approved by security holders

1,103,166

$

1.93

96,834

Equity Compensation Plans not approved by security holders

297,298

$

1.50

NA

1,400,464

$

1.84

96,834

		Prior to January 1, 2006, the Company accounted for employee stock-based compensation under the recognition and measurement principles of Accounting Principles Board Opinion (“APB”) No. 25, “Accounting for Stock Issued to Employees,” and related Interpretations, as permitted by SFAS No. 123, “Accounting for Stock-Based Compensation”. Under the recognition principles of APB No. 25, compensation expense related to restricted stock and performance units was recognized in the financial statements. However, APB No. 25 generally did not require the recognition of compensation expense for stock options because the exercise price of these instruments was generally equal to the fair value of the underlying common stock on the date of grant, and the related number of shares granted were fixed at that point in time.
		Effective January 1, 2006, the Company adopted the fair value recognition provisions of SFAS No. 123(R), “Share-Based Payment”. In addition to recognizing compensation expense related to restricted stock and performance units, SFAS No. 123(R) also requires recognition of compensation expense related to the estimated fair value of stock options. The Company adopted SFAS No. 123(R) using the modified-prospective-transition method. Under that transition method, compensation expense recognized subsequent to adoption includes: (a) compensation cost for all share-based payments granted prior to, but not yet vested as of January 1, 2006, based on the values estimated in accordance with the original provisions of SFAS No. 123, and (b) compensation cost for all share-based payments granted subsequent to January 1, 2006, based on the grant-date fair values estimated in accordance with the provisions of SFAS No. 123(R). Consistent with the modified-prospective-transition method, the Company’s results of operations for prior periods have not been adjusted to reflect the adoption of FAS 123(R). For the three months ended June 30, 2008 the Company recognized $88,425 (2007 — $nil) in compensation expense in the consolidated statement of operations.

15

---

Table of Contents

16.		COMMON STOCK WARRANTS AND OTHER OPTIONS
		As of June 30, 2008, the Company has 7,260,026 warrants to purchase the Company’s common stock outstanding that were not granted under shareholder approved equity compensation plans at prices ranging between $1.20 and $3.00 per share with expiration dates between August 2007 and September 2012 as follows:

						Weighted
		Outstanding				Average Exercise
		Warrants				Price
Warrants and options outstanding , March 31, 2008			7,260,026			$	1.67
Granted			—				—
Exercised			—				—
Cancelled or expired			—				—
Warrants exercisable March 31, 2008			7,260,026			$	1.62
Exercise price range		$	1.20 to $3.00
Weighted average remaining life		3.16 Years

17.		SEGMENT INFORMATION
		The Company’s only operating segment consists of dental products and oral hygiene products sold by Remedent Inc., Remedent N.V., Sylphar N.V. and Remedent Asia Ltd.. Since the Company only has one segment, no further segment information is presented.
		Customers Outside of the United States

		June 30, 2008				June 30, 2007
U.S. sales		$	2,158,900			$	33,777
Foreign sales			1,476,579				1,210,880
		$	3,635,479			$	1,244,657

18.		COMMITMENTS
		Real Estate Lease
		The Company leases its 26,915 square feet office and warehouse facility in Deurle, Belgium from an unrelated party pursuant to a nine year lease commencing December 20, 2001 at a base rent of $6,838 per month ($11,097 per month at June 30, 2008). The minimum aggregate rent to be paid over the remaining lease term based upon the conversion rate for the € at March 31, 2008 is $359,773.
		Minimum monthly lease payments for real estate, and all other leased equipment for the next three years are as follows based upon the conversion rate for the (Euro) at June 30, 2008.

March 31, 2009		$	240,734
March 31, 2010		$	76,896
March 31, 2011		$	42,143
Total:		$	359,773

		Factoring Agreement
		On April 24, 2008, the Company entered into a Factoring Agreement (“Agreement”) with First Community Financial, a division of Pacific Western Bank (“First Community”) whereby First Community may purchase, from time to time, on a limited recourse basis such of the Company’s accounts now existing or hereafter created and arising out of the sale of goods or service by the Company. The factoring credit facility limit is $1,000,000 and amounts factored are subject to an interest rate of prime plus 2%. Security for the factoring credit facility is a first charge over all the assets of the Company. The Agreement shall remain in effect until October 16, 2008 and may be renewed for successive six month periods unless terminated under certain conditions.

16

---

Table of Contents

OEM Agreement

On June 30, 2008, the Company entered into an OEM Agreement (“Agreement”) with SensAble Technologies, Inc., a corporation under the laws of Delaware (“SensAble”) whereby the Company will integrate SensAble products and technology into the Company’s system. The Agreement provides the Company with the exclusive right to distribute certain SensAble products throughout the world for a period of twelve (12) months from the date of the Agreement. The Company has the option and right to extend the initial twelve (12) month exclusivity period for another twelve (12) months. The term of the Agreement will be for two years and began on June 30, 2008.

19. SUBSEQUENT EVENTS

None

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward Looking Statements

          The discussion contained herein is for the three months ended June 30, 2008 and 2007. The following discussion should be read in conjunction with the Company’s condensed consolidated financial statements and the notes to the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2008. In addition to historical information, this section contains “forward-looking” statements, including statements regarding the growth of product lines, optimism regarding the business, expanding sales and other statements. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many factors including continued market acceptance of our products. In addition, actual results could vary materially based on changes or slower growth in the oral care and cosmetic dentistry products market; the potential inability to realize expected benefits and synergies; domestic and international business and economic conditions; changes in the dental industry; unexpected difficulties in penetrating the oral care and cosmetic dentistry products market; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors. Factors that could cause or contribute to any differences are discussed in “Risk Factors” and elsewhere in the Company’s annual report on Form 10-KSB filed on July 15, 2008 with the Securities and Exchange Commission. Except as required by applicable law or regulation, the Company undertakes no obligation to revise or update any forward-looking statements contained in this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2008. The information contained in this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2008 is not a complete description of the Company’s business or the risks associated with an investment in the Company’s common stock. Each reader should carefully review and consider the various disclosures made by the Company in this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2008 and in the Company’s other filings with the Securities and Exchange Commission.

17

---

Table of Contents

Overview

          We design, develop, manufacture and distribute cosmetic dentistry products. Leveraging our knowledge of regulatory requirements regarding dental products and management’s experience in the needs of the professional dental community, we have developed a family of teeth whitening products for both professional and “Over-The-Counter” use, that are distributed in Europe, Asia and the United States. We manufacture many of our products in its facility in Deurle, Belgium as well as outsourced manufacturing in China. We distribute our products using both its own internal sales force and through the use of third party distributors. As a result of this approach, in just four years we have established dealers in 35 countries encompassing, Europe, Asia, Latin America, the Pacific Rim and the Middle East.

          For the quarter ending June 30, 2008, 73% of our revenue has been generated by our Belgian Subsidiaries, Remedent NV and Sylphar NV, 23% by our US organization and 4 % by our Asian Subsidiary.

          Our products can be generally classified into the following categories: professional dental products and “Over-The Counter” tooth whitening products. In the fall of 2006, we launched a proprietary veneer technology product line called GlamSmile™. GlamSmile veneers are ultra thin claddings made from a mixture of a hybrid composite and porcelain materials which are attached to the front of the patient’s teeth. Because GlamSmile veneers are so thin, the dentist does not need to remove healthy tooth structure leaving the patient’s healthy tooth structure intact results in several important benefits: (i) no local anesthesia is required to prepare the teeth; (ii) reduced (if any) tooth sensitivity post-procedure; and (iii) the process is reversible. In addition, in the three months ended March 31, 2006, a variation of our MetaTray ^® product named iWhite ^® was introduced to our global retail distribution network. We introduced MetaTray in August 2005, our next generation of products targeted for the professional dentist market. MetaTray is a completely self-contained whitening system that can be administered by dentists.

          Our products are distributed utilizing our Distributor Assisted Marketing programs. As a result of this approach, in just four years we have established dealers in 35 countries encompassing, Europe, Asia, Latin America, the Pacific Rim and the Middle East.

          In June 2007, we completed a private placement of 5,600,000 shares of our common stock at $1.25 per share and warrants to purchase up to 4,200,000 shares of common stock at an exercise price of $1.55 per share to certain institutional and accredited investors for an aggregate purchase price of $7,000,000, of which we received proceeds of $5,771,192, net of costs.

          We also received net proceeds of $15,900 on the exercise of 10,000 warrants.

          On February 19, 2008, the Company entered into a formal debt conversion and Registration Rights Agreement with a former investor of the Company. The debt was in the amount of $50,536 and was for past services and obligations attributable to the operations of the Company and its California subsidiaries. In exchange for the debt the Company issued 31,558 common shares of its capital stock.

Our Critical Accounting Policies

          The discussion and analysis of the Company’s financial condition and results of operations is based upon the Company’s consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, including those related to bad debts, intangible assets, income taxes, and contingencies and litigation, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these

18

---

Table of Contents

estimates under different assumptions or conditions. The Company believes that certain critical accounting policies affect its more significant judgments and estimates used in the preparation of its consolidated financial statements: revenue recognition, inventory valuation, research and development costs, stock-based compensation, impairment of long-lived assets and conversion of foreign currencies. These accounting policies are discussed in “ITEM 6 — MANAGEMENT’S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION” contained in the Company’s Annual Report on Form 10-KSB for the fiscal year ended March 31, 2008, as well as in the notes to the March 31, 2008 consolidated financial statements. There have not been any significant changes to these accounting policies since they were previously reported at March 31, 2008.

Results of Operations

          Results of Operations for the three months ended June 30, 2008 compared with the three months ended June 30, 2007.

          The following table presents our consolidated statements of loss, as a percentage of sales, for the periods indicated.

		For the three months ended
		June 30,
		2008				2007
NET SALES			100.00	%			100.00	%
COST OF SALES			34.92	%			53.46	%
GROSS PROFIT			65.08	%			46.54	%
OPERATING EXPENSES
Research and development			3.44	%			2.36	%
Sales and marketing			18.47	%			8.29	%
General and administrative			31.09	%			59.81	%
Depreciation and amortization			2.51	%			5.27	%
TOTAL OPERATING EXPENSES			55.50	%			75.74	%
INCOME (LOSS) FROM OPERATIONS			9.58	%			(29.21	)%
Other income (expense)			(0.49	)%			(2.20	)%
INCOME (LOSS) BEFORE INCOME TAXES		9.09%					(31.41	)%
NET INCOME (LOSS)			9.09	%			(31.41	)%

  Net Sales

          We experienced a sales increase for the three months ended June 30, 2008 of $2,390,822, or 192.1%, to $3,635,479 as compared to $1,244,657 for the three months ended June 30, 2007. The increase in sales was due to the increased sales of the GlamSmile Product Group, an increase by $1,206,366 or 337,8% as well as increased sales of OTC products, more specifically the iWhite and Remesense product lines by $1,184,456 or 260,7%.

Cost of Sales

          Our cost of sales increased for the three months ended June 30, 2008 by $603,996, or 90.8%, to $1,269,424 as compared to $665,428 for the three months ended June 30, 2007. Accordingly, cost of

19

---

Table of Contents

sales, as a percentage of net sales, decreased from 53.5% for the quarter ended June 30, 2007 to 34.9% for the quarter ended June 30, 2008. Cost of sales has decreased both because of increased sales of higher margin products and improved cost efficiencies.

          We have re-organized our production process and have increased our in-house manufacturing resulting in lower costs than our previously outsourced third party manufacturing. We continue to closely monitor and look for new strategies to optimize and improve our current processes in order to decrease our costs.

Gross Profit

          Our gross profit increased by $1,786,826 or 308.5%, to $2,366,055 for the three month period ended June 30, 2008 as compared to $579,229 for the three month period ended June 30, 2007. Our gross profit as a percentage of sales increased from 46.5% in the three months ended June 30, 2007 to 65% for the three months ended June 30, 2008. The increase in gross profit is the result of the increased sales of higher margin products and the decrease in cost of sales as discussed above.

Operating Expenses

           Research and Development . Our research and development expenses increased to $124,958 for the three months ended June 30, 2008 as compared to $29,389 for the three months ended June 30, 2007, an increase of 325%. The principal reason for this increase is the ongoing efforts to develop new products and improve existing products to meet the highest standards on the market.

           Sales and marketing costs . Our sales and marketing costs increased $568,058 or 550%, to $671,299 for the three months ended June 30, 2008 as compared to $103,241 for the three months ended June 30, 2007. The increase is largely due to increased provisions for commissions in relation to our sales people and increased marketing costs to promote our products in new acquired markets into different countries.

           General and administrative costs . Our general and administrative costs for the three months ended June 30, 2008 and 2007 were $1,130,313 and $744,481, respectively, representing an increase of $385,832 or 51.8%. The increase in general and administrative costs as compared to the prior year is the result of our investments made to increase customer support concurrent with the launch of our GlamSmile veneers product line in both Europe and the US.

           Depreciation and amortization . Our depreciation and amortization increased $25,627 or 39%, to $91,261 for the three months ended June 30, 2008 as compared to $65,634 for the three months ended June 30, 2007. The increase is mostly due to the investment in a semi-automatic production machine for the production of our foam strips, which will allow us to significantly increase our production capacity. This investment allowed us to streamline and improve production significantly with resultant increases in capacity and quality as well as decreased costs. Secondly, investments are being made in software and related hardware to bring the design of veneers to the next level which will allow the dentist to modify the design of the final product, gaining substantial time in the production process.

           Net interest expense was $17,723 for the three months ended June 30, 2008 as compared to $27,437 for the three months ended June 30, 2007, a decrease of $9,714, or 35%. Interest expense has decreased primarily because of decreased utilization of our available bank credit line.

Liquidity and Capital Resources

20

---

Table of Contents

Cash and Cash equivalents

          Our balance sheet at June 30, 2008 reflects cash and cash equivalents of $1,467,692 as compared to $1,728,281 as of March 31, 2008, a decrease of $260,589. The decrease of cash and cash equivalents is primarily as a result of the increase in accounts receivable as at June 30, 2008.

Operations

          Net cash used by operations was $135,979 for the three months ended June 30, 2008 as compared to net cash provided by operations of $1,298,484 for the three months ended June 30, 2007. The decrease in net cash provided by operations for the three months ended June 30, 2008 as compared to the three months ended June 30, 2007 is primarily attributable to an increase in accounts receivable of $541,000 and a reduction of accounts payable of $148,000.

Investing activities

          Net cash used in investing activities totaled $287,613 for the three months ended June 30, 2008 as compared to net cash used in investing activities of $50,364 for the three months ended June 30, 2007. Cash used in investing activities in the three months ended June 30, 2008 was mainly for equipment to be used in the production process of Veneers, additional hardware equipment in relation to support our GlamSmile product line in combination with our new designed software, enabling the dentist to interfere in the production process, investments made for moldings concerning the GlamSmile product group and moldings for new OTC products.

Financing activities

          Net cash provided by financing activities totaled $116,897 for the three months ended June 30, 2008 as compared to $5,511,867 for the three months ended June 30, 2007. Net cash provided from financing activities in the three month period ended June 30, 2007 was higher than in the three months ended June 30, 2008 because of the net cash proceeds received by the Company from a Private Placement, which took place at the end of the quarter ended June 30, 2007, with net proceeds received in the three month period ended June 30, 2007 totaling $6,045,294 offset by the partial repayment of our existing Credit Line in the amount of $522,226.

          During the next nine months, cash raised from our recent private placement (which occurred in June 2007) will be used to finance our current liabilities, reduce the Facility at Fortis Bank and fund our future investments, largely related to our GlamSmile product.

          During the three months ended June 30, 2008 and June 30, 2007, we recognized an increase in cash and cash equivalents of $52,279 and $6,756, respectively, from the effect of exchange rates between the Euro and the US Dollar.

Off-Balance Sheet Arrangements

          At June 30, 2008, we did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

          Not Applicable.

21

---

Table of Contents

Item 4T. Controls and Procedures

Disclosure Controls and Procedures

          The Company maintains disclosure controls and procedures designed to ensure that information required to be disclosed in its reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized, and reported within the required time periods and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer (our Principal Accounting Officer), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objective, and management is required to exercise its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

          Management conducted an evaluation, under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of June 30, 2008. Based on this evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2008.

Change in Internal Control Over Financial Reporting

          There have been no changes in the Company’s internal controls over financial reporting identified in connection with the evaluation of disclosure controls and procedures discussed above that occurred during the quarter ended June 30, 2008 or subsequent to that date that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

22

---

Table of Contents

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

     To the best knowledge of management, there are no material legal proceedings pending against the Company.

Item 1A. Risk Factors

     During the quarter ended June 30, 2008, there were no material changes to the risk factors previously reported by the Company in its Annual Report on Form 10-KSB for the fiscal year ended March 31, 2008.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

     None.

Item 3. Defaults Upon Senior Securities

     None.

Item 4. Submission Of Matters To A Vote Of Security Holders

     No matters were submitted to a vote of security holders during the quarter ended June 30, 2008.

Item 5. Other Information

     None.

23

---

Table of Contents

Item 6. Exhibits

Exhibit No				Description
	2.1			Stock Exchange Agreement with Resort World Enterprises, Inc. (1)
	3.1			Articles of Incorporation of Jofran Confectioners International, Inc., a Nevada corporation, dated July 31, 1986 (1)
	3.2			Amendment to Articles of Incorporation changing name from Jofran Confectioners International, Inc., a Nevada corporation, to Cliff Typographers, Inc., a Nevada corporation, dated July 31, 1986 (1)
	3.3			Amendment to Articles of Incorporation changing name from Cliff Typographers, Inc., a Nevada corporation, to Cliff Graphics International, Inc., a Nevada corporation, dated January 9, 1987 (1)
	3.4			Amendment to Articles of Incorporation changing name from Cliff Graphics International, Inc., a Nevada corporation, to Global Golf Holdings, Inc., a Nevada corporation, dated March 8, 1995 (1)
	3.5			Amendment to Articles of Incorporation changing name from Global Golf Holdings, Inc., a Nevada corporation, to Dino Minichiello Fashions, Inc., a Nevada corporation, dated November 20, 1997 (1)
	3.6			Amendment to Articles of Incorporation changing name from Dino Minichiello Fashions, Inc., a Nevada corporation, to Resort World Enterprises, Inc., a Nevada corporation, dated August 18, 1998 (1)
	3.7			Amendment to Articles of Incorporation changing name from Resort World Enterprises, Inc., a Nevada corporation, to Remedent , Inc., dated October 5, 1998 (1)
	3.8			Amended and Restated Articles of Incorporation changing name from Remedent, USA, Inc. to Remedent, Inc. and to effect a one-for-twenty reverse stock split on June 3, 2005 (2)
	3.9			Amended and Restated Bylaws (2)
	4.1			Specimen of Stock Certificate (3)
	4.2			Form of Subscription Agreement (4)
	4.3			Form of Warrant for Common Stock (4)
	4.4			Form of Registration Rights Agreement (4)
	4.5			Form of Warrant for Unit (5)
	4.6			Form of Warrant for Common Stock (6)
	10.1			Distribution Agreement, dated April 10, 2008, by and between Remedent N.V. and GlamTech USA, Inc. (7)
	10.2			Factoring Agreement between Remedent, Inc. and First Community Financial, a division of Pacific Western Bank, dated April 24, 2008 (8)
	10.3			OEM Agreement between Remedent, Inc. and SensAble Technologies, Inc., dated June 30, 2008 (9)
	31.1			Certifications of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act.*
	31.2			Certifications of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act.*
	32.1			Certifications of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act.*
	32.2			Certifications of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act.*

 

*		Filed herewith.
(1)		Incorporated by reference from Registration Statement on Form SB-2 filed with the SEC on July 24, 2002.
(2)		Incorporated by reference from Form 8-K filed with the SEC on June 8, 2005.
(3)		Incorporated by reference from Form SB-2 filed with the SEC on August 4, 2005.
(4)		Incorporated by reference from Form 8-K filed with the SEC on July 11, 2005.
(5)		Incorporated by reference from Form SB-2/A filed with the SEC on October 26, 2005
(6)		Incorporated by reference from Form 8-K filed with the SEC on June 27, 2007.

24

---

Table of Contents

(7)		Incorporated by reference from Form 8-K filed with the SEC on April 15, 2008.
(8)		Incorporated by reference from Form 8-K filed with the SEC on April 30, 2008.
(9)		Incorporated by reference from Form 8-K filed with the SEC on July 7, 2008.

25

---

Table of Contents

SIGNATURES

     Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REMEDENT, INC.
Date: August 19, 2008	By:	/s/ Robin List
		Name:	Robin List
		Title:	Chief Executive Officer
Date: August 19, 2008	By:	/s/ Philippe Van Acker
		Name:	Philippe Van Acker
		Title:	Chief Financial Officer

26